The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis

OBJECTIVE: Non-alcoholic steatohepatitis (NASH) is characterized by hepatic steatosis, inflammation and fibrosis. There are currently no targeted therapies for NASH. We developed a liver-specific LXR inverse agonist, SR9238, which effectively reduces hepatic lipogenesis in models of obesity and hepa...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffett, Kristine, Welch, Ryan D., Flaveny, Colin A., Kolar, Grant R., Neuschwander-Tetri, Brent A., Burris, Thomas P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354919/
https://www.ncbi.nlm.nih.gov/pubmed/25830098
http://dx.doi.org/10.1016/j.molmet.2015.01.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354919/
https://www.ncbi.nlm.nih.gov/pubmed/25830098
http://dx.doi.org/10.1016/j.molmet.2015.01.009

Ejemplares similares